Manish Shah, MD of Weill-Cornell Medical Center, NYC discusses FOLFIRI versus FOLFOX7 will this randomized trial advance the treatment paradigms…
Manish Shah, MD of Weill-Cornell Medical Center, NYC answers the question does the Asian population differ from the western populations…
What direction is research taking in the field of myeloproliferative neoplasms (MPNs)? Dr. Laura Michaelis of Medical College of Wisconsin…
On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) conference, Andrew spends a few minutes with…
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Robert West, PhD, from University College London, London, UK, discusses…
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Sergio Quezada, PhD, from University College London, London, UK, discusses…
Dr. William Wierda of MD Anderson Cancer Center shares his insights on the tornado of research activity out of ASH…
Patient Power founder, Andrew Schorr, caught up with CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology…
Dr. Michael Keating, from MD Anderson Cancer Center, joins us for another segment in our Ask The Expert series, answering…
Dr. Andrew Zelenetz of Memorial Sloan Kettering Cancer Center describes the expanding CLL and lymphoma armamentarium on location at the…
CLL experts Drs. Zeev Estrov, Nicole Lamanna and Michael Keating at our town meeting at MD Anderson Cancer Center in…
On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Claire Harrison,…
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Elaine Vickers, PhD, Founder and Principal Trainer of Science Communicated,…
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the role of neoadjuvant chemotherapy and…
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Immune checkpoint inhibitors in combination with…
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Clinical trials in bladder cancer with…
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Adjuvant radiation v. chemo-RT v. chemotherapy…
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine…
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, provides an overview if the Phase III clinical…
Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the current treatment landscape in chronic lymphocytic…
Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the impact of the clinical trial of…
Thomas J Kipps, MD from the University of California, San Diego, CA, provides an overview of the clinical trial RESONATE-2…
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase…
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, discusses the importance of targeting proliferanting and quiescent chronic…
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the…
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the…
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the…
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the…
Barbara Eichhorst, MD from the Ludwig-Maximilians University, Munich, Germany, provides an overview of combination studies presented at the American Society…
At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL., Dr Naval Daver from the University…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses recommendations for the utilization of molecular factors in treatment planning…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses ongoing clinical trials that will establish a clinical role for…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers that have been identified in prognosis and risk…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers have greater impact on risk of recurrence than…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses Genetic Testing in Prostate Cancer at ASCO GU 2016
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses using new therapies earlier in prostate cancer may returns better…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses significant off-target adverse events from novel treatments directed at molecular…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses new recently discovered novel targets for CCRPC at ASCO GU…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses galeterone and alternative splicing does this agent differ from approved…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses the agents currently available or in research pipelines than target…
Tam Constantine, MD from Peter MacCallum Cancer Centre & St. Vincent’s Hospital Melbourne, Melbourne, Australia, gives an overview of the…
Eileen Kaner, MSc, PhD, Hon FRCP gives an overview of a session focusing lifestyle behaviour and cancer prevention presented at…
Alan Burnett, MD from Cardiff University, Cardiff, UK discusses the new technology developments in the field of acute myeloid leukemia…
Dr Naughton communicates the clinical actionability of a Low Risk/Low Likelihood of Benefit BCI result in his practice.
What is CLL? How and where does it start? CLL experts Dr. Nicole Lamanna of Columbia University Medical Center and…
From our Ask the Expert series, CLL expert Dr. Michael Keating of MD Anderson Cancer Center answers a common CLL…
Dr. Michael Keating of MD Anderson Cancer Center answers the question: Does CLL return more aggressively after relapse than it…
Toni Choueiri, MD of Dana Farber gives us Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium from San Francisco
Dr. Toni Choueiri, MD of Dana Farber gives an ASCO GU 2016 Update on Clear Cell and non-Clear Cell Renal…
Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses how Avelumab is tolerable for patients according to JAVELIN…
Dr. Andrea B. Apolo, MD from the National Cancer Institute discusses the next steps and moving Checkpoint Inhibitors from metastatic…
Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C),…
Dr. Nima Sharifi, MD of Cleveland Clinic comments on how investigators are now looking to use new therapies earlier within…
Dr. Nima Sharifi, MD at Cleveland Clinic gives an overview of his presentation Androgen Receptor New Ways of Targeting the…
Dr. Nima Sharifi, MD at Cleveland Clinic discusses the ALLIANCE trial and the combinations of CYP17 and AR inhibitors in…
Dr. Nima Sharifi, MD of Cleveland Clinic discusses the potential role for combinations of CYP17 inhibitors and AR inhibitors in…
Dr. Nima Sharifi, MD of Cleveland Clinic answers the question How does CYP17 inhibitors and novel androgen receptor inhibitors affect…
Nima Sharifi, MD of Cleveland Clinic discusses the new Androgen Receptor Signaling and the new targets and agents for advanced…
Dr. Petros Grivas, MD at Cleveland Clinic discusses the correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features…
Dr. Petros Grivas, MD at Cleveland Clinic discusses atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) at…
Dr. Petros Grivas, MD at Cleveland Clinic discusses the evaluation of response to enzalutamide consecutively after disease progression on abiraterone…
Dr. Petros Grivas, MD of Cleveland Clinic discusses The association of D4, 3-keto-abi (D4A) and response to abiraterone in castration-resistant…
Dr. Walter Stadler of The University of Chicago Cancer Center @UCCancerCenter discusses Choosing predictive markers for PD-1 and PD-L1 inhibitors…
“Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and…
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of venetoclax (ABT-199) for the treatment…
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of the Resonate-2 clinical trial of…
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase…
Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target…
Jacqueline Barrientos, MD, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data…
Jacqueline Barrientos, MD, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides…
Jacqueline Barrientos, MD, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that…
Dr. Walter Stadler of the University of Chicago discusses how Checkpoint inhibitors iwill mpact outcomes for advanced RCC
Dr. Walter Stadler discusses his experience with FDA approved Nivolumab and PD-1 and PD-L1 inhibitors in RCC
Patient Power founder Andrew Schorr along with patient advocate Carol Preston, on location at the 2015 American Society of Hematology…
How far have we progressed in the field of CLL research? Patient advocate Carol Preston, on location at the 2015…
Is there hope for people with Hodgkin Lymphoma? Dr. John Sweetenham, Executive Medical Director of the Huntsman Cancer Institute, says,…
Are clinical trials still valid as a means for treatment? On location at the 2015 American Society of Hematology (ASH),…
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial…
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses CheckMate 025 phase III trial: Outcomes by key baseline factors…
Watch patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) conference, discusses the new molecule,…
As part of our coverage of the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naveen Pemmaraju…
Lymphoma expert Dr. Jeff Sharman, on location at 2015 American Society of Hematology (ASH) meeting, reviews the advancement of follicular…
At the 2015 American Society of Hematology (ASH) conference, patient advocate Carol Preston and Dr. Christopher Yasenchak, from US Oncology…
Endocrine therapy may cause many bothersome side effects, often affecting a patients compliance. Dr Naughton suggests BCI as a tool…
Is there current research for the 20 percent of CML (Chronic Myelogenous Leukemia) patients who are resistant to imatinib mesylate…
Patient Power founder caught up with leading CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH)…
Are clinical trials still a good idea for patients? Is there still a place for chemo? Who should get genetic…
At the 2015 American Society of Hematology (ASH) annual meeting, myeloma expert Dr. James Berenson joined Patient Power to discuss…
What is the REVEAL study, and why is it so important to polycythemia vera (PV) patients? On location at the…
CLL expert Dr. Jeff Sharman, on location at the ASH (American Society of Hematology) 2015 meeting, Dr. Jeff Sharman, shares…
As part of Patient Power coverage from the 2015 American Society of Hematology (ASH), myeloma experts Dr. Noopur Raje, Dr.…
As part of our coverage of the 2015 American Society of Hematology annual meeting, MPN expert Dr. Richard Silver joined…
Dr. Zeev Estrov, of MD Anderson Cancer Center, discusses fatigue in CLL patients including findings from ongoing research on JAK2…
Breast Cancer Index (BCI) validation studies included both women treated with aromatase inhibitors (AI) and women treated with tamoxifen (Tam).…
As part of our coverage of the 2015 American Society of Hematology annual meeting, myeloma expert Dr. Paul Richardson joined…
Patient Power founder Andrew Schorr led an expert panel as they reviewed CLL news from the 2015 American Society of…
As part of our coverage from the 2015 American Society of Hematology (ASH), a panel of MPN experts including Dr.…
On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naval Daver…
At the European Cancer Congress (ECC) 2015, Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rachael Crayton, Oncology Specialist Nurse from Central Manchester NHS…
Patient Power founder Andrew Schorr talks with MPN expert Dr. Srdan Verstovsek to reflect on the final days of the…
Watch coverage from the 2015 American Society of Hematology (ASH) meeting with myeloma expert Dr. Robert Orlowski from MD Anderson…
Renowned CLL expert Dr. Jeff Sharman answered your questions LIVE, as we broadcasted from the 2015 American Society of Hematology…
From ASH 2015, patient advocates Andrew Schorr and Carol Preston are joined by myeloma specialist Dr. Gareth Morgan as they…
Patient advocates and hosts Andrew Schorr and Carol Preston review the highlights from the first few days of the 2015…
At the American Society of Hematology (ASH) meeting in Orlando, CLL expert Dr. Jan Burger discussed the result from the…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute,…
The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie,…
In the era of molecular medicine, there is now a tool called Breast Cancer Index (BCI) to help physicians determine…
The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie,…
The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie,…
The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie,…
Saad Usmani, MD Levine Cancer Institute Charlotte, NC discusses the Dana Farber IFM 2009 Phase III Study of the Intergroupe…
Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses how…
Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses the…
Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses the fact that Precision Medicine Coming…
Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses Pre Transplant Depression Linked to Lower…
Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses a Phase 3 Randomized Trial Support…
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Ixazomib Has Not Shown…
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about how Elotuzumab Shows Benefits…
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Daratumumab will Play Increasingly…
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about new ASH 2015 Data…
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Chemotherapy-induced nausea and vomiting (CINV) remains a concern for many cancer patients. At the United Kingdom Oncology Nursing Society (UKONS)…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ruth Hammond, Vascular Access and IV Nurse Practitioner, and…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Henry, President Elect of the UKONS, and Teaching…
Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of the…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson…
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed…
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Entospletinib Why Its Different Than Fostamatinib
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology talks about how CLL has been Transformed in Last…
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses ASH 2015 highlights as Bcl-2, BTK, and PI3…
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC…
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC…
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC…
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC…
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC…
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses Imetelstat Pilot Study Data Released…
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PRM-151 Phase III Study…
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PERSIST-1 Phase III Study…
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how the COMFORT II Study…
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Real World Experience with Approved…
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses R-CHOP With or Without Bortezomib…
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses the New CAR T-Cell Studies…
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Natural Therapeutic Partners for BCR…
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Ibrutinib in Mantle Cell Lymphoma…
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Atrial Fibrillation in Patients with…
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses ABT-199 Data Released at ASH…
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Real World Experience with Ibrutinib and…
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Novel Nucleoside Analog Ribose Sugar…
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Map Kinase Pathway P-38 in…
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Choosing a BCR Signaling Inhibitor in…
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about ASH 2015 Highlights for Myeloma…
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses the latest Advances In B-Cell Lymphoma…
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Second Generation B2K Inhibitors Look Promising ACP-196…
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of…
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib -…
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Idelalisib + Ofatumumab as First Line Therapy…
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about How the Idelalisib+Ofatumumab Trial Affect Planning…
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Redistribution Lymphocytosis in…
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Utilizing Idelalisb…
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Combining Antibody…
Press brief by Mark C. Walters, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Walters provides…
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Chimeric Antigen Receptor…
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives an Update of…
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives and update on…
Dr. Joshua Brody, MD – @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses an update…
Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at…
Join us for a provocative program format that includes point and counterpoint presentations and interactive case discussions to provide varied…
Dr. Morie Gertz of the Mayo Clinic shares his overview of this year’s American Society of Hematology (ASH) meeting. He…
Dr. Sagar Lonial of the Winship Cancer Institute of Emory University in Atlanta, Georgia, speaks from the American Society of…
Dr. Kenneth Anderson of the Dana-Farber Cancer Institute and Vice President of the American Society for Hematology (ASH) shares about…
Dr. Saad Usmani of the Levine Cancer Institute in Charlotte, North Carolina, gives his perspective on the treatment options for…
Dr. Meletios Dimopoulus provides an update on the Eloquent-2 Trial: A Phase 3 Randomized, Open-Label Study of elotuzumab in Combination…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Toby Talbot, MB BS, of Royal Cornwall Hospitals NHS…
Dr. Saad Usmani reports on the clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple…
Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis – a Matched Case Control Study Dr. Ashutosh Wechalekar National Amyloidosis…
Richard Henry, President Elect of the United Kingdom Oncology Nursing Society (UKONS), and Teaching Fellow at the School of Nursing…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Tim Anstiss, MB, MEd, D.Occ.Med, MFSEM, of the Academy…
Dr. Damian Green of Seattle Cancer Care Alliance presented at the 2015 ASH Annual Meeting in Orlando. In the following…
Dr. Ryan Cassaday of Seattle Cancer Care Alliance presented a poster at the 2015 ASH Annual Meeting in Orlando. In…
Myeloma UK provides information and support for individuals affected by multiple myeloma. At the United Kingdom Oncology Nursing Society (UKONS)…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Berman, MBBS, MRCGP, FRCP, of The Christie NHS…
Dr. Naughton recognizes the difference between risk of recurrence and likelihood of benefit from extended endocrine therapy, noting the two…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer…
Somatic Profiles – NGS Testing
MPN expert Dr. Rami S. Komrokji, Clinical Director of the Malignant Hematology Department at the Moffitt Cancer Center, shares his…
The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use…
As part of our Ask the Expert series, MPN expert Dr. Jamile Shammo of Rush University Medical Center responds to…
@OncEd Presents Dr. Barb Melosky – Best of Lung Cancer – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Winson Cheung – Best of Health Services / Survivorship – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Scott North – Best of Prostate – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Christian Kollmannsberger – Best of Non-Prostate – best of ASCO 2015 Vancouver
@OncEd Presents Dr. Stephen Chia – Best of Breast Cancer – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Michael Smylie – Best of Melanoma – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Howard Lim – Best of Non-Colorectal – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Sharlene Gill – Best of Colorectal – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Kerry Savage – Bet of Lymphoma – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Cheryl Ho – Best of Head and Neck – Best of ASCO 2015 Vancouver
@OncEd Presents Pancreatic Tumour Board – 2015
@OncEd Presents Dr. Allan Covens – BRCA Mutations in Ovarian Cancer – 2015
@OncEd Presents Dr. Scott Berry – First Line treatment of Unresectable Metastatic Colorectal Cancer – 2015
@OncEd Presents Dr. Natasha Leighl – Best of Lung Cancer – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Martina Trinkaus – Best of Hematology – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Eric Chen – Best of Head and Neck – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Kala Sridhar – Best of Non-Prostate – Best of ASCO 2015 Toronto
@OncEd Presents Dr. S̩bastien Hotte РBest of Prostate РBest of ASCO 2015 Toronto
@OncEd Presents Dr. Ron Burkes – Best of Colorectal – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Anthony Brade – Best of Radiation Oncology – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Yoo-Joung Ko – Best of Non-Colorectal – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Marcus Butler – Best of Melanoma – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Philippe Bedard – Best of Breast Cancer – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Benoit Samson – Best of Survivorship – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Jamil Asselah – Best of Breast Cancer – Best of ASCO 2015 Montreal
@OncEd Presents Dr. F̩lix Couture РBest of Colorectal РBest of ASCO 2015 Montreal
@OncEd Presents Dr. John Storring – Best of Hematology – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Benoit Samson – Best of Lung Cancer – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Fr̩d̩ric Lemay РBest of GI Cancers РBest of ASCO 2015 Montreal
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Joanne Upton, Skin Cancer Advanced Nurse Practitioner at The…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager, Myeloma UK, Edinburgh,…
@OncEd Presents Dr.Fran̤ois Patenaude РBest of Renal Cancer РBest of ASCO 2015 Montreal
@OncEd Presents Dr.Cristiano Ferrario – Best of Prostate – Best of ASCO 2015 Montreal
@OncEdPresents Dr. David Hogg – Best of Melanoma – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Jennifer Knox – Gastric, Biliary & Hepatocellular Cancers – GUGI 2015
@OncEd Presents Dr. Jean-Bernard Durand – Assessing the Impact Cardio-Toxicities Have on Patients When Continuing Chemotherapeutic Agents
@OncEd Presents Dr. Scot Dowden – Pancreatic Cancer – GUGI 2015
@OncEd Presents Dr. Nathaniel Bouganim – Best of Head and Neck – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Scott Berry – Colorectal Cancers – GUGI 2015
@OncEd Presents Dr. Eric Winquist – Bladder and Testis Cancer – GUGI 2015
@OncEd Presents Dr. Georg Bjarnason – Renal Cell Cancer – GUGI 2015
@OncEd Presents Dr. S̩bastien Hotte РCastrate Refractory Disease РGUGI 2015
@OncEd Presents Dr. Andrew Loblaw – Early Disease – GUGI 2015
@OncEd Presents Dr. Neil Fleshner – Hormone Sensitive Disease – GUGI 2015
@OncEd Presents Dr. Daniel Renouf – Individualized Treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 3 – Best…
@OncEd Presents Dr. Sharlene Gill – Individualized treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 1 – Best…
@OncEd Presents Dr. Winson Cheung – Individualized Treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 2 – Best…
@OncEd Presents Dr. Cynthia Wu – Breakfast Symposium: Blood Clots in Cancer – Best of Oncology West 2015
@OncEd Presents Dr. Ralph Wong – Best of GI Colorectal Cancer – Best of Oncology West 2015
@OncEd Presents Dr. Ralph Wong – Best of GI-Colorectal Cancer – Best of Oncology West 2015
@OncEd Presents Dr. Joanna Vergidis – Best of GU Cancers – Best of Oncology West 2015
@OncEd Presents Dr. Christine Simmons – Best of Breast Cancer – Best of Oncology West 2015
@OncEd Presents Dr. Kerry Savage – Best of Lymphoma- Best of Oncology West 2015